Adam J. Platt

BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Direct visualisation and measurement of lung microstructure reveal insights into extracellular matrix dysregulation in COPD.

Direct visualisation and measurement of lung microstructure reveal insights into extracellular matrix dysregulation in COPD.

Journal: Respiratory research

Published: February 12, 2026

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers.

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers.

Journal: Journal of hepatology

Published: November 14, 2025

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

Journal: Journal of hepatology

Published: November 14, 2025

Integrated miRNA-mRNA network analysis identifies miR-182-5p as a potential regulator in COPD pathogenesis.

Integrated miRNA-mRNA network analysis identifies miR-182-5p as a potential regulator in COPD pathogenesis.

Journal: Frontiers in medicine

Published: November 10, 2025

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 08, 2025

First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.

First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.

Journal: The Journal of allergy and clinical immunology

Published: June 25, 2025

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Journal: RMD open

Published: May 20, 2025

ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma.

ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma.

Journal: Respiratory research

Published: March 31, 2025

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

Journal: ERJ open research

Published: February 07, 2025

A novel SPECT-CT imaging platform for quantifying in vivo lung cytokine signals in COPD.

A novel SPECT-CT imaging platform for quantifying in vivo lung cytokine signals in COPD.

Journal: ERJ open research

Published: November 26, 2024

A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.

A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055.

Journal: iScience

Published: November 11, 2024

Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD.

Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD.

Journal: Respiratory research

Published: October 09, 2024

Showing 1-12 of 54

Last Updated: 09/26/2026